Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide

被引:55
|
作者
Dhillon, J [1 ]
Dickinson, JM [1 ]
Sole, K [1 ]
Mitchison, DA [1 ]
机构
[1] ROYAL POSTGRAD MED SCH,DEPT INFECT DIS & BACTERIOL,LONDON W12 0HS,ENGLAND
关键词
D O I
10.1128/AAC.40.3.552
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The efficacies of rifampin-containing preventive regimens were measured in Cornell model mice in which an initially severe infection with Mycobacterium tuberculosis K37Rv was first treated for 7 weeks with 25 mg of isoniazid and 1,000 mg of pyrazinamide per kg of body weight in the diet and then with one of four test regimens given by daily oral gavage for 6 weeks, These regimens were 15 mg of rifampin per kg alone (R), rifampin plus 25 mg of isoniazid per kg (RH), rifampin plus 150 mg of pyrazinamide per kg (RZ), or rifampin plus isoniazid and pyrazinamide (RHZ), The interval between the rifampin gavage and the gavage with the other drugs ranged from 10 to 45 min, so that interference with rifampin absorption did not occur, Mice were sacrificed at 11 and 20 weeks after the termination of chemotherapy, with each killing being preceded by 3 weeks of high-dose dihydrocortisone treatment, Entire spleens and lungs were cultured, The proportions of mice,vith positive spleens at either killing time were 73% of 43 mice treated with R, 63% of 41 mice treated with RH, 65% of 43 mice treated with RZ, and 53% of 45 mice treated with RHZ, a just significant (P = 0.04) trend for fewer positive spleens with increasing numbers of drugs in the regimen, However, no trend was found in the corresponding proportions of mice with positive spleens or lungs, which were 81, 63, 65, and 71% for mice treated with R, RH, RZ, and RHZ, respectively, Thus, in the Cornell model, R alone, RH, RZ, and RHZ all had similar efficacies.
引用
收藏
页码:552 / 555
页数:4
相关论文
共 50 条
  • [1] Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment
    van Hest, R
    Baars, H
    Kik, S
    van Gerven, P
    Trompenaars, MC
    Kalisvaart, N
    Keizer, S
    Borgdorff, M
    Mensen, M
    Cobelens, F
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 39 (04) : 488 - 496
  • [2] TREATMENT OF TUBERCULOSIS WITH ISONIAZID, RIFAMPIN AND PYRAZINAMIDE
    BRANDLI, O
    DREHER, D
    MORGER, D
    [J]. SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1993, 123 (25) : 1300 - 1306
  • [3] Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide
    Gangadharam, PRJ
    Geeta, N
    Hsu, YY
    Wise, DL
    [J]. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 1999, 3 (06) : 515 - 520
  • [4] ANTAGONISM BETWEEN ISONIAZID AND THE COMBINATION PYRAZINAMIDE-RIFAMPIN AGAINST TUBERCULOSIS INFECTION IN MICE
    GROSSET, J
    TRUFFOTPERNOT, C
    LACROIX, C
    JI, B
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (03) : 548 - 551
  • [5] The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis
    Akos Somoskovi
    Linda M Parsons
    Max Salfinger
    [J]. Respiratory Research, 2
  • [6] The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis
    Somoskovi, A
    Parsons, LM
    Salfinger, M
    [J]. RESPIRATORY RESEARCH, 2001, 2 (03) : 164 - 168
  • [7] Paradoxical Effect of Isoniazid on the Activity of Rifampin-Pyrazinamide Combination in a Mouse Model of Tuberculosis
    Almeida, Deepak
    Nuermberger, Eric
    Tasneen, Rokeya
    Rosenthal, Ian
    Tyagi, Sandeep
    Williams, Kathy
    Peloquin, Charles
    Grosset, Jacques
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (10) : 4178 - 4184
  • [8] Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months
    Nolan, CM
    Goldberg, SV
    [J]. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2002, 6 (11) : 952 - 958
  • [9] Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients
    McIlleron, H
    Wash, P
    Burger, A
    Norman, J
    Folb, PI
    Smith, P
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (04) : 1170 - 1177
  • [10] STABILITY OF ISONIAZID, RIFAMPIN AND PYRAZINAMIDE IN SUSPENSIONS USED FOR THE TREATMENT OF TUBERCULOSIS IN CHILDREN
    SEIFART, HI
    PARKIN, DP
    DONALD, PR
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1991, 10 (11) : 827 - 831